Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS [NYSE]
Novartis AG
Index- P/E31.37 EPS (ttm)3.09 Insider Own9.30% Shs Outstand2.29B Perf Week3.83%
Market Cap235.18B Forward P/E15.18 EPS next Y6.38 Insider Trans0.00% Shs Float2.27B Perf Month6.57%
Income7.10B PEG4.04 EPS next Q1.34 Inst Own10.20% Short Float0.19% Perf Quarter13.06%
Sales49.58B P/S4.74 EPS this Y-43.60% Inst Trans0.95% Short Ratio2.29 Perf Half Y12.00%
Book/sh23.84 P/B4.06 EPS next Y11.01% ROA5.70% Target Price107.00 Perf Year1.75%
Cash/sh4.48 P/C21.64 EPS next 5Y7.77% ROE13.20% 52W Range69.18 - 99.84 Perf YTD2.59%
Dividend3.09 P/FCF47.20 EPS past 5Y-6.50% ROI8.60% 52W High-2.97% Beta0.59
Dividend %3.19% Quick Ratio0.70 Sales past 5Y-1.90% Gross Margin71.20% 52W Low40.04% ATR1.28
Employees110000 Current Ratio0.90 Sales Q/Q0.40% Oper. Margin18.80% RSI (14)69.50 Volatility0.98% 1.04%
OptionableYes Debt/Eq0.70 EPS Q/Q-5.40% Profit Margin14.30% Rel Volume0.55 Prev Close96.92
ShortableYes LT Debt/Eq0.52 EarningsJan 26 BMO Payout91.00% Avg Volume1.93M Price96.88
Recom1.00 SMA204.05% SMA506.96% SMA20010.96% Volume1,071,326 Change-0.04%
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Jan-21-21 10:29AM  
07:04AM  
Jan-20-21 12:15PM  
10:30AM  
Jan-15-21 09:11AM  
08:14AM  
Jan-14-21 04:35PM  
03:11PM  
Jan-12-21 04:31PM  
02:58PM  
08:15AM  
Jan-11-21 04:30PM  
Dec-31-20 08:52AM  
Dec-28-20 07:30AM  
07:00AM  
Dec-22-20 09:08AM  
Dec-21-20 10:16AM  
Dec-18-20 07:04PM  
05:08PM  
04:50PM  
07:34AM  
Dec-17-20 12:29PM  
09:25AM  
Dec-16-20 01:31PM  
07:15AM  
Dec-15-20 07:17PM  
10:37AM  
07:27AM  
01:15AM  
Dec-14-20 01:15AM  
Dec-11-20 09:29AM  
Dec-09-20 09:45AM  
09:00AM  
Dec-08-20 04:23PM  
10:00AM  
Dec-05-20 10:00AM  
Dec-04-20 12:30PM  
08:00AM  
Dec-03-20 04:33PM  
04:12AM  
Dec-02-20 04:09PM  
Nov-25-20 09:30AM  
Nov-24-20 08:12AM  
07:13AM  
01:00AM  
Nov-23-20 07:00PM  
Nov-20-20 11:20AM  
10:17AM  
09:44AM  
08:42AM  
07:37AM  
Nov-19-20 04:30PM  
10:00AM  
09:43AM  
01:15AM  
Nov-18-20 01:29AM  
Nov-16-20 01:54PM  
Nov-15-20 06:52AM  
Nov-13-20 10:00AM  
Nov-10-20 05:06PM  
04:46PM  
Nov-06-20 07:47AM  
02:00AM  
01:15AM  
Nov-05-20 04:11PM  
10:12AM  
09:57AM  
01:15AM  
Nov-03-20 10:54AM  
Nov-02-20 04:33PM  
02:45PM  
01:27PM  
01:15AM  
Oct-30-20 01:06PM  
11:23AM  
02:15AM  
Oct-29-20 10:51AM  
08:32AM  
07:30AM  
04:32AM  
Oct-28-20 07:41AM  
04:53AM  
02:35AM  
02:15AM  
Oct-27-20 04:29PM  
10:49AM  
07:59AM  
02:11AM  
02:00AM  
Oct-26-20 02:15AM  
Oct-23-20 09:08AM  
Oct-19-20 01:05PM  
Oct-16-20 01:31PM  
Oct-15-20 09:00AM  
Oct-12-20 05:47PM  
Oct-06-20 06:44PM  
10:31AM  
Oct-03-20 06:20AM  
Oct-02-20 09:52AM  
Oct-01-20 01:15AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; Dyno Therapeutics Inc.; and Olema Oncology. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures LtdFormer 10% OwnerJun 30Buy17.00125,0002,125,0001,181,258Jul 02 04:16 PM